Inhibition of p38α MAPK rescues cardiomyopathy induced by overexpressed β2-adrenergic receptor, but not β1-adrenergic receptor
暂无分享,去创建一个
S. Vatner | D. Vatner | J. Sadoshima | Yibin Wang | S. Engelhardt | Lin Yan | Pallavi S. Peter | J. Brady | Wei Chen
[1] Q. Han,et al. Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling. , 2005, Pharmacology & therapeutics.
[2] K. Schlüter,et al. p38 MAP‐kinase in cultured adult rat ventricular cardiomyocytes: expression and involvement in hypertrophic signalling , 2005, European journal of heart failure.
[3] Jie Ren,et al. Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction. , 2005, Journal of molecular and cellular cardiology.
[4] J. Molkentin,et al. STRESS signaling pathways that modulate cardiac myocyte apoptosis. , 2005, Journal of molecular and cellular cardiology.
[5] Heping Cheng,et al. Subtype-specific β-adrenoceptor signaling pathways in the heart and their potential clinical implications , 2004 .
[6] A. Marks,et al. Novel therapeutic approaches for heart failure by normalizing calcium cycling , 2004, Nature Reviews Drug Discovery.
[7] C. Niesler,et al. p38 and JNK have distinct regulatory functions on the development of apoptosis during simulated ischaemia and reperfusion in neonatal cardiomyocytes , 2004, Basic Research in Cardiology.
[8] S. Vatner,et al. Propranolol prevents enhanced stress signaling in Gsα cardiomyopathy: potential mechanism for β-blockade in heart failure , 2004 .
[9] E. Lakatta,et al. Enhanced Gi Signaling Selectively Negates &bgr;2-Adrenergic Receptor (AR)– but Not &bgr;1-AR–Mediated Positive Inotropic Effect in Myocytes From Failing Rat Hearts , 2003, Circulation.
[10] Jing Liu,et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[11] D. Burkhoff,et al. &bgr;-Blockers Restore Calcium Release Channel Function and Improve Cardiac Muscle Performance in Human Heart Failure , 2003, Circulation.
[12] Timothy E Hewett,et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. , 2003, The Journal of clinical investigation.
[13] S. Vatner,et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. , 2003, The Journal of clinical investigation.
[14] Attila Kovacs,et al. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. , 2003, The Journal of clinical investigation.
[15] B. Kobilka,et al. Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. , 2003, The Journal of clinical investigation.
[16] H. Krumholz,et al. β-Blocker Therapy in Heart Failure: Scientific Review , 2002 .
[17] H. Krumholz,et al. beta-Blocker therapy in heart failure: scientific review. , 2002, JAMA.
[18] D. Kass,et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[19] C. O'connor,et al. Inotropic therapy for heart failure: an evidence-based approach. , 2001, American heart journal.
[20] S. Vatner,et al. β-adrenergic cardiac hypertrophy is mediated primarily by the β1-subtype in the rat heart , 2001 .
[21] S. Vatner,et al. Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. , 2001, Journal of molecular and cellular cardiology.
[22] B. Kobilka,et al. β2-Adrenergic Receptor-induced p38 MAPK Activation Is Mediated by Protein Kinase A Rather than by Gi or Gβγ in Adult Mouse Cardiomyocytes* , 2000, The Journal of Biological Chemistry.
[23] G. Jennings,et al. Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing beta(2)-adrenergic receptors in the heart. , 2000, Cardiovascular research.
[24] K. Schlüter,et al. Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat. , 2000, American journal of physiology. Cell physiology.
[25] W. Colucci,et al. p38 Mitogen-activated Protein Kinase Pathway Protects Adult Rat Ventricular Myocytes against β-Adrenergic Receptor-stimulated Apoptosis , 2000, The Journal of Biological Chemistry.
[26] B. Wilson,et al. Coupling Function of Endogenous α1- and β-Adrenergic Receptors in Mouse Cardiomyocytes , 2000 .
[27] G. Dorn,et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. , 2000, Circulation.
[28] S. Vatner,et al. beta-adrenergic receptor signaling: an acute compensatory adjustment-inappropriate for the chronic stress of heart failure? Insights from Gsalpha overexpression and other genetically engineered animal models. , 2000, Circulation research.
[29] M. Bristow. β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .
[30] Catherine Communal,et al. Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein , 1999 .
[31] S. Steinberg. The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. , 1999, Circulation research.
[32] S. Vatner,et al. β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse , 1999 .
[33] M. Lohse,et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[34] John W. Adams,et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[35] M. Packer. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. , 1998, Progress in cardiovascular diseases.
[36] J Ross,et al. Cardiac Muscle Cell Hypertrophy and Apoptosis Induced by Distinct Members of the p38 Mitogen-activated Protein Kinase Family* , 1998, The Journal of Biological Chemistry.
[37] S. Vatner,et al. Adverse Effects of Chronic Endogenous Sympathetic Drive Induced by Cardiac Gsα Overexpression , 1996 .
[38] E. Lakatta,et al. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. , 1995, Molecular pharmacology.
[39] R. Lefkowitz,et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. , 1994, Science.
[40] S. Jamieson,et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.
[41] R. Lefkowitz,et al. Adrenergic receptors in the heart. , 1982, Annual review of physiology.
[42] K. Swedberg,et al. PROLONGATION OF SURVIVAL IN CONGESTIVE CARDIOMYOPATHY BY BETA-RECEPTOR BLOCKADE , 1979, The Lancet.